** Shares of cancer therapy maker ImmunityBio IBRX.O rise 21.5% to $4.05
** IBRX says U.S. FDA has authorized co to provide a new version of the BCG vaccine, called recombinant BCG (rBCG), to help address a shortage of the traditional Tice BCG vaccine used to treat bladder cancer
** The shortage of Merck's MRK.N Tice BCG has affected 57% of U.S. urologists, making it difficult for them to treat patients - IBRX
** IBRX has also been awarded patents for the combination of rBCG with another drug called Anktiva, approved last year, for the treatment of bladder cancer
** IBRX says it is working with the Serum Institute of India to provide of vials of rBCG to address the shortage
** Brokerage BTIG views FDA authorization as a "positive tailwind" for Anktiva, driving physician use
** IBRX fell ~51% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。